Anjeso (meloxicam IV) / Baudax Bio 
Welcome,         Profile    Billing    Logout  
 7 Diseases   1 Trial   1 Trial   163 News 


12»
  • ||||||||||  Anjeso (meloxicam IV) / Baudax Bio
    Journal:  Bioequivalence of Meloxicam Nanocrystal Injection in Healthy Chinese Volunteers. (Pubmed Central) -  Sep 5, 2024   
    Additionally, four subjects (16.7%) experienced five instances of adverse events in the T group, while five subjects (21.7%) experienced five instances of adverse events in the R group. This trial indicated the potential bioequivalence between the T and R products under fasting conditions, based on pharmacokinetic and safety profile.
  • ||||||||||  Anjeso (meloxicam IV) / Baudax Bio
    The Comparative Efficacy of IV and Oral Analgesics for Third Molar Dental Extraction Pain (Exhibition Hall/Poster Area) -  Jul 18, 2024 - Abstract #IASP2024IASP_877;    
    IV diclofenac, meloxicam ketorolac, and oral acetaminophen/ ibuprofen combination had values > 0.63 while celecoxib, indomethacin, and tramadol were substantially lower. Our results demonstrate a high degree of efficacy for IV meloxicam, diclofenac, and ketorolac with a maximum responder rates (i.e., those reaching ?50%
  • ||||||||||  Anjeso (meloxicam IV) / Baudax Bio
    Preclinical, Journal:  Refinement of the motorised laminectomy-assisted rat spinal cord injury model by analgesic treatment. (Pubmed Central) -  Jan 20, 2024   
    Weekly Basso Beattie and Bresnahan (BBB) scores served as markers for functionality together with Novel Object Recognition test (NOR) at week 8 and terminal histopathology using area of vacuolisation and live neuronal count from the ventral horns of spinal cord. It was concluded that the usage of analgesia improved animal wellbeing while having no effects on the functional aspects of the animal model in comparison to the animals that received no analgesics.
  • ||||||||||  Anjeso (meloxicam IV) / Baudax Bio
    Enrollment change, Trial termination, Surgery:  Safety and Pharmacokinetics of N1539 in Children 2 to <17 Years of Age Following Surgery (clinicaltrials.gov) -  Sep 13, 2023   
    P4,  N=19, Terminated, 
    However, further studies are needed to determine the pharmacodynamic properties and clinical efficacy of MLX for the treatment of inflammatory disease after single and multiple dosages. N=90 --> 19 | Recruiting --> Terminated; Anjeso (N1539) NDA Withdrawn
  • ||||||||||  PK/PD data, Journal:  PHARMACOKINETICS OF ORAL FLUNIXIN MEGLUMINE, MELOXICAM, OR GABAPENTIN IN THREE BLACK RHINOCEROS (DICEROS BICORNIS). (Pubmed Central) -  Jul 14, 2023   
    Oral flunixin meglumine achieved a lower C (range 170.67-664.38 ng/ml) in this study compared with the mean C (1,207 ng/ml) reported in a similar study in white rhinoceroses (Ceratotherium simum), but some overlap in range of values was noted. Oral flunixin meglumine T (range 1.05-10.78 h) and half-life (range 3.88-14.85 h) values in black rhinoceroses was similar to mean values reported in white rhinoceroses (3 and 8.3 h, respectively).
  • ||||||||||  Anjeso (meloxicam IV) / Baudax Bio
    Trial completion:  Meloxicam for Pain Management After Total Joint Arthroplasty (TJA) (clinicaltrials.gov) -  Jun 1, 2023   
    P3,  N=231, Completed, 
    Oral flunixin meglumine T (range 1.05-10.78 h) and half-life (range 3.88-14.85 h) values in black rhinoceroses was similar to mean values reported in white rhinoceroses (3 and 8.3 h, respectively). Recruiting --> Completed
  • ||||||||||  Anjeso (meloxicam IV) / Baudax Bio
    Trial completion date, Trial primary completion date:  Meloxicam for Pain Management After Total Joint Arthroplasty (TJA) (clinicaltrials.gov) -  Nov 8, 2022   
    P3,  N=200, Recruiting, 
    All 3 treatments provided reliable sedation; however, alfaxalone (4 mg/kg, IM) combined with hydromorphone (0.1 mg/kg, IM) may be a better choice for painful procedures. Trial completion date: Dec 2022 --> Jun 2023 | Trial primary completion date: Dec 2022 --> Jun 2023
  • ||||||||||  Anjeso (meloxicam IV) / Baudax Bio
    Preclinical, Journal:  Preclinical studies of a high drug-loaded meloxicam nanocrystals injection for analgesia. (Pubmed Central) -  Sep 20, 2022   
    The acetic acid-induced writhing tests, hot plate tests and hind paw incision experiments demonstrated that the MLXNCs had significant analgesic effects. The findings provide insights into the developed high drug-loaded MLXNCs and provide new therapeutic options for acute and chronic pain management.
  • ||||||||||  Anjeso (meloxicam IV) / Baudax Bio
    Enrollment open:  Meloxicam for Pain Management After Total Joint Arthroplasty (TJA) (clinicaltrials.gov) -  May 17, 2022   
    P3,  N=200, Recruiting, 
    These results improve our understanding on the residue depletion of meloxicam from chickens' reproductive tracts and egg products and provide WDIs to help ensure food safety for humans consuming eggs from treated laying hens. Not yet recruiting --> Recruiting
  • ||||||||||  Journal:  Nonopioid drugs for pain. (Pubmed Central) -  Mar 3, 2022   
    Not yet recruiting --> Recruiting No abstract available
  • ||||||||||  meloxicam / Generic mfg.
    Journal:  Meloxicam clinical effects (Pubmed Central) -  Feb 25, 2022   
    A number of studies have demonstrated the efficacy and safety of meloxicam with different methods of its administration (per oral (p/o), intramuscularly (i/m)) in the treatment of pain syndrome in the lower back, with OA, etc. Recent studies concern intravenous (i/v) meloxicam (30 mg) administration with moderate and severe postoperative pain syndrome. Today, the most commonly pain therapy scheme using meloxicam includes step-by-step administration of injectable and oral forms: meloxicam i/m (1.5 ml) for 3-5 days, followed by a transition to p/o (7.5-15 mg) intake for 14 days, or complex therapy with meloxicam (Amelotex), with muscle relaxant and B vitamins.
  • ||||||||||  Anjeso (meloxicam IV) / Baudax Bio
    Preclinical, Journal:  The Evaluation of Meloxicam Nanocrystals by Oral Administration with Different Particle Sizes. (Pubmed Central) -  Feb 19, 2022   
    Additionally, plasma concentration-time curves showed that the AUC of MLX-NCs-C were 3.58- and 2.92-fold greater than those of MLX-NCs-A and MLX-NCs-B, respectively. These results indicate that preparing MLX in nanocrystals can effectively improve the bioavailability, and the particle size of nanocrystals is an important factor in transmission and absorption.
  • ||||||||||  Anjeso (meloxicam IV) / Baudax Bio
    PK/PD data, Journal:  Pharmacokinetics of intravenous meloxicam, ketoprofen and tolfenamic acid in chukar partridge (Alectoris chukar). (Pubmed Central) -  Feb 10, 2022   
    MLX, KETO and TA offer treatment in chukar partridges for various conditions with an absence of adverse reactions and properties such as short elimination half-life and low volume of distribution. However, there is a need to establish the safety and adverse effects of repeated administration, pharmacokinetics of other administration routes and pharmacological efficacy of MLX, KETO and TA in chukar partridges.
  • ||||||||||  Anjeso (meloxicam IV) / Baudax Bio
    Clinical, Journal, HEOR:  Economic Impact of Preoperative Meloxicam IV Administration in Total Knee Arthroplasty: A Randomized Trial Sub-Study. (Pubmed Central) -  Oct 30, 2021   
    P3b
    Patients in the meloxicam IV 30 mg vs placebo group (n = 93 vs 88) incurred an adjusted $2,266 (95% CI: -$1,035, $5,116; p = 0.1689) lower total hospital costs and an adjusted 8.6% (95% confidence interval [CI]: -2.0%, 18.1%; p = 0.1082) shorter LOS. While statistically non-significant, based on 95% CIs, the results from this sub-study may suggest a favorable impact associated with meloxicam IV 30 mg on hospital costs and LOS.
  • ||||||||||  Anjeso (meloxicam IV) / Baudax Bio
    Meloxicam IV for the Management of Pain Following Radiofrequency Ablation (RFA) of the Spine: A Case Study () -  Sep 15, 2021 - Abstract #PAINWeek2021PAINWeek_47;    
    [3]In this case study, three of the 12 subjects treated with meloxicam IV had a reduction from baseline in pain intensity during the post procedural recovery period before discharge, and six subjects reported no pain compared to baseline. At the 24-hour post procedure assessment, five subjects had reductions in pain intensity from baseline, and one subject continued to be pain free.
  • ||||||||||  Anjeso (meloxicam IV) / Baudax Bio
    Journal:  National Variation in Congenital Heart Surgery Outcomes. (Pubmed Central) -  Sep 1, 2021   
    Contrary to traditional thinking, a substantial portion of potential improvements that could be realized on a national scale were related to variability among lower-risk cases. These findings suggest modifications to our current approaches to optimize care and outcomes in this population are needed.
  • ||||||||||  PK/PD data, Journal:  Impact of lactation on pharmacokinetics of meloxicam in goats. (Pubmed Central) -  Oct 24, 2020   
    Moreover, AUC ratio between milk and plasma, which represent drug milk penetration, for both IV and IM administrations was less than 1 (about 0.3). In conclusion, pharmacokinetic parameters of meloxicam are not significantly altered by lactation for either the IV or IM routes of administration and this drug does not require a different dosage regimen for lactating animals.
  • ||||||||||  meloxicam / Generic mfg., Anjeso (meloxicam IV) / Baudax Bio
    Journal:  IV meloxicam (Anjeso) for pain. (Pubmed Central) -  Sep 16, 2020   
    In conclusion, pharmacokinetic parameters of meloxicam are not significantly altered by lactation for either the IV or IM routes of administration and this drug does not require a different dosage regimen for lactating animals. No abstract available
  • ||||||||||  meloxicam / Generic mfg., Anjeso (meloxicam IV) / Baudax Bio
    Clinical, P3 data, Journal:  A Phase 3, Randomized, Placebo-Controlled Evaluation of the Safety of Intravenous Meloxicam Following Major Surgery. (Pubmed Central) -  Aug 19, 2020   
    Over the treatment period, meloxicam IV was associated with a 23.6% (P = .0531) reduction in total opioid use (9.2 mg morphine equivalent) compared to placebo-treated subjects. The results suggest that meloxicam IV had a safety profile similar to that of placebo with respect to numbers and frequencies of adverse events and reduced opioid consumption in subjects with moderate to severe postoperative pain following major elective surgery.
  • ||||||||||  meloxicam / Generic mfg., Anjeso (meloxicam IV) / Baudax Bio
    Journal:  Study of Top-down and Bottom-up Approaches by Using Design of Experiment (DoE) to Produce Meloxicam Nanocrystal Capsules. (Pubmed Central) -  Jul 22, 2020   
    Different NS preparation methodologies proved to have a direct influence on the following capsuling process and consequently, in the dissolution rate. This study also proved that residual DMSO in nanosuspension after precipitation process could affect the freeze-drying process, which might further alter the redispersion and influence the downstream processes.
  • ||||||||||  meloxicam / Generic mfg., Anjeso (meloxicam IV) / Baudax Bio
    HEALTHCARE RESOURCE UTILIZATION (HRU) ASSOCIATED WITH PREOPERATIVE MELOXICAM IV IN COLORECTAL SURGERY (S105bc) -  May 19, 2020 - Abstract #SSAT2020SSAT_159;    
    Observed reductions in HRU in this analyses were associated with reductions in opioid use and ORADEs in meloxicam IV vs. placebo subjects. This study demonstrates that perioperative administration of meloxicam IV 30 mg in subjects undergoing colorectal surgery results in reductions in HRU.
  • ||||||||||  meloxicam / Generic mfg., Anjeso (meloxicam IV) / Baudax Bio
    HEALTHCARE RESOURCE UTILIZATION (HRU) ASSOCIATED WITH PREOPERATIVE MELOXICAM IV IN COLORECTAL SURGERY () -  May 4, 2020 - Abstract #DDW2020DDW_3945;    
    Observed reductions in HRU in this analyses were associated with reductions in opioid use and ORADEs in meloxicam IV vs. placebo subjects. This study demonstrates that perioperative administration of meloxicam IV 30 mg in subjects undergoing colorectal surgery results in reductions in HRU